Q9NXA8 (SIR5_HUMAN) Homo sapiens (Human)
NAD-dependent protein deacylase sirtuin-5, mitochondrial UniProtKBInterProSTRINGInteractive Modelling
Available Structures
26 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Sirt5 is an NAD-dependent protein lysine demalonylase and desuccinylase |
Heteromer P68431; | 100 | 1×ZN; 1×NAD; | |||
| histone lysine desuccinylase Sirt5 in complex with succinyl peptide H2BK120 |
Heteromer P62807; | 100 | 1×ZN; 1×CL; 1×GOL; | |||
| Sirt5 is an NAD-dependent protein lysine demalonylase and desuccinylase |
Heteromer P68431; | 100.0 | 1×ZN; 1×NHE; | |||
| The bicyclic intermediate structure provides insights into the desuccinylation mechanism of SIRT5 |
Heteromer P68431; | 100.0 | 1×ZN; | |||
| Crystal structure of human SIRT5 in complex with succinylated Prx1 fragment |
Heteromer Q06830; | 100 | 1×ZN; 2×DMS; | |||
| The bicyclic intermediate structure provides insights into the desuccinylation mechanism of SIRT5 |
Heteromer P68431; | 100 | 1×ZN; 1×CGK; | |||
| Crystal structure of human Q140L-SIRT5 in complex with succinylated Prx1 fragment |
Heteromer Q06830; | 99.62 | 1×ZN; 1×GOL; 1×CL; | |||
| Crystal structure of human SIRT5 in complex with succPrx1 and ADP ribose |
Heteromer Q06830; | 100 | 1×ADP; 1×ZN; | |||
| histone lysine desuccinylase Sirt5 in complex with succinyl peptide H2AK95 |
Heteromer P04908; | 100 | 1×ZN; | |||
| Crystal structure of human Q140L-SIRT5 in complex with succinylated Prx1 fragment and ADP ribose |
Heteromer Q06830; | 99.62 | 1×ZN; 1×ADP; | |||
| histone lysine desuccinylase Sirt5 in complex with succinyl peptide H3K122 |
Heteromer Q71DI3; | 100 | 1×ZN; 2×GOL; | |||
| histone lysine desuccinylase Sirt5 in complex with succinyl peptide H4K91 |
Heteromer P62805; | 100.0 | 1×ZN; | |||
| Crystal structure of human N141V-SIRT5 in complex with succinylated Prx1 fragment |
Heteromer Q06830; | 99.62 | 1×ZN; 1×CL; | |||
| Crystal Structure of Human Sirtuin Homolog 5 in Complex with Suramin | homo-2-mer | 100.0 | 2×ZN; 1×SVR; | |||
| Human Sirt5 in complex with stalled peptidylimidate intermediate of inhibitory compound 29 | monomer | 100 | 1×ZN; 1×BV8; 5×EDO; 2×BU2; 2×DMS; | |||
| Crystal structure of human Sirt5 in complex with an internally quenched fluorescent substrate GluIQF | monomer | 100 | 1×ZN; 1×NA; 1×GUA; | |||
| Crystal Structure of SIRT5 in Complex with a Coumarin-Labelled Succinyl Peptide | monomer | 100 | 1×ZN; 1×MCM; | |||
| Crystal structure of human SIRT5 in complex with diazirine inhibitor 9 | monomer | 100 | 1×8VG; 1×PEG; 1×ZN; | |||
| Crystal structure of human Sirt5 in complex with the fluorogenic tetrapeptide substrate P13 | monomer | 100 | 1×ZN; 1×MCM; | |||
| Crystal structure of human Sirt5 in complex with the fluorogenic tetrapeptide substrate P15 | monomer | 100 | 1×ZN; 1×MCM; | |||
| Crystal Structure of Human Sirtuin homolog 5 | monomer | 100.0 | 1×ZN; 1×APR; 1×EPE; | |||
| Human SIRT5 bound to Succ-IDH2 and Carba-NAD | monomer | 100 | 1×ZN; 1×CNA; | |||
| Crystal structure of SIRT5 complexed with a fluorogenic small-molecule substrate SuBKA | monomer | 100.0 | 1×PHQ; 1×SLL; 1×MCM; 1×ZN; | |||
| Crystal structure of human Sirt5 in complex with Fluor-de-Lys peptide and resveratrol | monomer | 100 | 1×ZN; | |||
| Structure of Apo Human SIRT5 | monomer | 100.0 | 1×ZN; | |||
| Structure of Apo Human SIRT5 P114T Mutant | monomer | 99.61 | 1×ZN; 1×EDO; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7x3p.1.A | monomer | 0.92 | 1×8VG; 1×ZN; | 100.00 | ||
3 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 3riy.1.A | monomer | 0.86 | 1×ZN; | 95.82 | ||
| Isoform 3 | 7x3p.1.A | monomer | 0.90 | 1×8VG; 1×ZN; | 98.06 | ||
| Isoform 4 | 7x3p.1.A | monomer | 0.89 | 1×ZN; | 100.00 | ||